Advertisement
News
Advertisement

GSK and Valeant Provide Regulatory Update On Retigabine

Mon, 11/02/2009 - 3:43am
GlaxoSmithKline and Valeant Pharmaceuticals International announced today that, on 30 October, they filed a New Drug Application with the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMEA), for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures. Retigabine is not approved or licensed anywhere in the world.
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading